Skip to main content
. 2019 Oct 17;10:1225. doi: 10.3389/fphar.2019.01225

Figure 5.

Figure 5

Forest plot comparing grade 3 or 4 adverse events with the RAL-based simplified regimen and the PIs/r-based traditional regimen in HIV-1 patients. (1) RAL = raltegravir. PIs/r = ritonavir-boosted protease inhibitor. NRTI = nucleoside or nucleotide reverse transcriptase inhibitor. (2) Study item displayed as the first author with the publication year. (3) I2 and P are the criteria of the heterogeneity test, with the —◆—pooled odds ratio, —¦— odds ratio and 95% confidence interval.